Brokerages Raise Paytm, Pine Labs Targets After UPI MDR Announcement

⚡ Key Financial Takeaways

Emkay raised Paytm's target price to Rs 2,400 and Pine Labs' to Rs 230, citing new MDR revenue streams.

NPCI introduced a 0.4% MDR on eligible UPI person-to-merchant transactions above Rs 2,000 effective October 15.

Emkay estimates UPI MDR will add Rs 11.2 billion to Paytm's revenue in FY28 and Rs 1.55 billion to Pine Labs.

Despite bullish analyst views, Pine Labs shares fell 6% to Rs 182.2, while Paytm gained 2.6% to Rs 1,775 on September 16.

Goldman Sachs suggests the MDR framework could lift Paytm's FY28 EBITDA estimate by 40-70% in a high-end scenario.

💡 Why It Matters

The introduction of MDR on UPI transactions marks a pivotal change in the economics of India's digital payment ecosystem. It provides payment companies with a sustainable revenue source beyond subsidies, potentially improving their long-term profitability and valuation metrics. For investors, this signals a maturing industry where operational efficiency and transaction volume directly translate to financial performance.

Analysts Revisit Valuations

Major brokerages have turned more bullish on Paytm and Pine Labs following the National Payments Corporation of India (NPCI) decision to introduce a Merchant Discount Rate (MDR) on select UPI transactions. The policy change, effective from October 15, imposes a 0.4% levy on eligible person-to-merchant transactions exceeding Rs 2,000. This development has prompted analysts to revise earnings estimates and target prices upward, viewing the MDR as a new, recurring revenue stream for payment infrastructure companies.

Target Price Revisions

Emkay Global Financial Services maintained 'Buy' ratings on both stocks but significantly raised their target prices. The brokerage lifted Paytm's target to Rs 2,400 from Rs 1,700 and Pine Labs' to Rs 230 from Rs 190. These revisions imply potential upside of approximately 35% and 26%, respectively, from the prices recorded on September 16.

Other institutions also adjusted their outlooks. Jefferies raised its target price for Paytm to Rs 2,150 and for Pine Labs to Rs 235. Similarly, JM Financial increased its Paytm target to Rs 2,150 from Rs 1,950, retaining its 'Buy' recommendation.

Revenue Projections

The financial impact of the MDR varies by company based on transaction volume and the share of revenue retained. Emkay estimates that the new levy will add Rs 678 per share to Paytm's valuation and about Rs 43 per share to Pine Labs.

For Paytm, Emkay projects UPI MDR revenue of Rs 11.2 billion in FY28, assuming a realised take rate of 10 basis points. JM Financial forecasts incremental revenue of Rs 2.1 billion in FY27, rising to Rs 4.7 billion in FY28, with incremental adjusted EBITDA reaching Rs 4.4 billion in FY28. Goldman Sachs noted that in a high-end scenario, the MDR framework could boost Paytm's FY28 EBITDA estimate by 40-70%.

For Pine Labs, Emkay estimates Rs 1.55 billion in UPI MDR revenue for FY28, based on a 6 basis point realised take rate. The brokerage noted that this revenue will accrue on existing payment infrastructure and merchant relationships.

Mixed Market Reaction

Despite the positive analyst commentary, market reactions were mixed on September 16. Paytm shares gained 2.6% to close at Rs 1,775. The stock has outperformed the broader market, rising 37.5% year-to-date in 2026, compared to an 11.2% decline in the Nifty 50.

In contrast, Pine Labs shares fell 6% to Rs 182.2, extending its year-to-date decline to 22.5%. Mobikwik, which did not have a readily available brokerage target in the supplied data, reversed early gains to trade 1.3% lower at Rs 198.3, with a year-to-date decline of 13.8%.

Structural Shift in UPI Economics

Emkay highlighted that the broader significance of this move is the shift from an annual subsidy model to a recurring, transaction-linked commercial revenue model for UPI acquiring. However, the actual earnings benefit will depend on each company's eligible transaction mix and specific exemptions or lower rates that apply under the new framework.

🏛️ Background & Context

Prior to this announcement, UPI acquiring largely relied on government subsidies and interchange fees. The new 0.4% MDR on transactions above Rs 2,000 introduces a direct cost to merchants, which is shared with payment aggregators and processors. This aligns the UPI model more closely with traditional card payment economics, where MDR is a standard revenue component.

👁️ What To Watch Next

Investors should monitor the actual realised take rates for Paytm and Pine Labs in upcoming quarters to see if they align with analyst assumptions (10 bps for Paytm, 6 bps for Pine Labs). Additionally, the final transaction mix eligible for the full 0.4% rate versus exempted or lower-rate categories will determine the ultimate revenue impact. Market sentiment towards Pine Labs may also be watched to see if the stock stabilises despite the recent drop.